HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.

Abstract
The increased chemosensitivity of oligodendroglial tumours has been associated with loss of heterozygosity (LOH) of the p arm of chromosome 1 and the q arm of chromosome 19 (LOH 1p/19q). Other clinical and molecular factors have also been identified as being prognostic and predictive of treatment outcome. We reviewed 105 patients with oligodendroglioma treated at a single centre over 20 years. Median survival in oligodendroglioma patients with LOH 1p/19q was significantly longer (10.9 vs. 2.0 years). In the anaplastic oligodendroglioma group, univariate analysis demonstrated decreased patient age, presentation with seizures, use of adjuvant chemotherapy and LOH 1p/19q as predictors of improved survival. Multivariate analysis confirmed LOH 1p/19q as a significant predictor of improved survival (hazard ratio, 3.4; p=0.015). Median survival in patients with anaplastic oligodendroglioma with LOH 1p/19q was 15.4 years vs. 1.2 years for those without LOH 1p/19q. This study confirms the utility of LOH 1p/19q as a prognostic marker in oligodendroglioma.
AuthorsJonathon F Parkinson, Vahid Afaghi, Cathy A Payne, Michael E Buckland, Janice M Brewer, Michael T Biggs, Nicholas S Little, Helen R Wheeler, Raymond J Cook, Kerrie L McDonald
JournalJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (J Clin Neurosci) Vol. 18 Issue 3 Pg. 329-33 (Mar 2011) ISSN: 1532-2653 [Electronic] Scotland
PMID21247767 (Publication Type: Journal Article)
CopyrightCopyright © 2010 Elsevier Ltd. All rights reserved.
Chemical References
  • Tumor Suppressor Protein p53
Topics
  • Adult
  • Aged
  • Brain Neoplasms (genetics, mortality, pathology)
  • Chemotherapy, Adjuvant
  • Chromosomes, Human, Pair 1 (genetics)
  • Chromosomes, Human, Pair 19 (genetics)
  • Drug Resistance, Neoplasm (genetics)
  • Female
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Loss of Heterozygosity
  • Male
  • Middle Aged
  • Oligodendroglioma (genetics, mortality, pathology)
  • Prognosis
  • Proportional Hazards Models
  • Tumor Suppressor Protein p53 (metabolism)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: